A takeover in its closing stages

Advanced Medical Solutions Group, the wound closure and care specialist, is in the final phase of a recommended cash takeover by H.B. Fuller, the US adhesives company. The latest announcements are Form 8.3 disclosures, filed by large holders during offer periods, several dated 12 October 2026. Attention now turns to when the deal completes and what remains outstanding.

The terms

The boards announced the agreed terms on 25 June 2026. H.B. Fuller Medical Adhesive Technologies Inc., a wholly owned subsidiary of H.B. Fuller, will pay 285 pence in cash for each AMS share, valuing the fully diluted equity at about £659m and the enterprise at about £715m. According to the announcement, the price is a 34.8% premium to the 212p close on 20 May 2026, the last business day before the offer period began, and 24.5% above the twelve-month high close of 229p. It equates to 12.9 times 2026 consensus IFRS EBITDA before synergies. The deal is structured as a court-sanctioned scheme of arrangement, unanimously recommended by directors. AMS chair Grahame Cook said it delivers attractive and certain value in cash to shareholders.

Background

H.B. Fuller's interest became public in May 2026, when AMS confirmed it had received an unsolicited proposal on 30 April and said it remained confident in its standalone prospects. AMS had also confirmed an approach from TA Associates, which later said it did not intend to make an offer. The scheme document was posted to shareholders on 20 July 2026, and shareholders approved the deal at meetings on 12 August 2026, according to H.B. Fuller. The announcement of that approval did not give the voting percentages. H.B. Fuller chief executive Celeste Mastin called the shareholder vote a significant milestone.

On the same date as the scheme document, 20 July, AMS issued a half-year trading update. It expected first-half revenue of about £115.2m, against £110.8m a year earlier, an increase of roughly 4%. Management attributed the modest growth to some orders shipping in early July rather than June, de-stocking linked to expanding direct sales in Europe, and a high prior-year comparator when a strategic partner in one division phased its orders. Integration of Peters Surgical and Syntacoll was described as on track, and the board expected full-year EBITDA in line with market expectations.

Why it matters

For shareholders, the question has moved from operating performance to deal certainty. The price is fixed in cash, so the remaining uncertainty concerns timing and conditions.

Conditions, risks and limitations

The scheme still needs Court sanction and delivery of the order to the Registrar of Companies. It also requires merger control clearance where required in Austria, Germany, the United Kingdom and the United States, and foreign investment clearance in Austria, France and Luxembourg. Any delay or an unexpected regulatory objection would push back completion materially. The offer price may be reduced by any dividend or distribution other than a specified final dividend, whose size has not been confirmed. Completion is expected by the end of calendar year 2026, according to the acquirer, and is not guaranteed. No confirmation that clearances have been received, or a revised timetable, has been published.